2026년 4월 25일 Pubmed Today

Nanotechnology-based drug delivery systems have significantly advanced modern pharmaceutics by addressing limitations associated with conventional therapies, including poor solubility, rapid systemic clearance, and nonspecific drug distribution. Among various nanocarriers, liposomes remain one of th…

Tuberculosis (TB) remains a leading infectious cause of morbidity and mortality worldwide, and major diagnostic and therapeutic challenges persist despite advances in microbiologic and molecular testing. Over the past decade, molecular imaging, especially with FDG PET/CT, has transformed our underst…

Large genomic deletions (≥1 kb) are a recurrent class of disease-causing lesions in monogenic disorders, frequently leading to complete gene inactivation or the loss of critical cis-regulatory elements. Addressing these defects in a therapeutically relevant manner requires integration modalit…

표적 대형 유전자 삽입의 기술 지형을 폭넓게 정리한 리뷰로, 기초·플랫폼 측면의 의미가 크다. 다만 환자 치료 성과나 임상 전환을 보여주는 데이터는 없어 당장 진료를 바꿀 수준은 아니다. 향후 어떤 플랫폼이 안전성, 적재 용량, 효율에서 우위를 확보하는지가 핵심이다.

Oesophageal squamous cell carcinoma (ESCC) represents a major global health burden, particularly in regions with high incidence rates, significantly affecting patient quality of life and survival outcomes. Recent advances in multi‑omics technologies have highlighted their potential in identif…

Targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with immune checkpoint inhibitors (ICIs) has improved survival across multiple cancer types, but the variability in patient response highlights the need for better predictive biomarkers. Existin…

장내미생물의 taxonomic 수준을 넘어 유전자 수준 특징을 활용해 ICI 반응 예측력을 높였다는 점이 핵심이다. 다중 암종에서 일반화 가능성을 보였지만, 아직은 후향적 모델 개발 성격이 강해 즉시 진료를 바꾸기보다는 후속 검증이 필요한 단계이다.

Real-time monitoring of kidney-infiltrating cytotoxic T lymphocytes (CTLs) is crucial for evaluating immunotherapy in renal cell carcinoma (RCC). However, existing imaging probes often exhibit “always-on” signals and poor renal clearance, limiting their ability to detect renal immune responses. Here…

면역치료 반응을 실시간으로 읽어내는 비침습적 바이오마커 플랫폼이라는 점에서 기술적 의미가 크다. 다만 환자 수가 적고 진단 보조 수준의 초기 검증에 그쳐, 당장 진료 표준을 바꿀 단계는 아니다. 향후 대규모 임상 검증과 경쟁 영상/체액 바이오마커 대비 우위가 핵심이다.

Colorectal cancer (CRC) with liver metastases (CRCLM) remains a clinical challenge. CXCL13 is widely recognized as a biomarker of immunotherapy response. However, the functional heterogeneity (protumor vs. antitumor) of CXCL13⁺CD4⁺ T cell subsets has long been controversial. Through in…

전이성 대장암의 면역미세환경을 설명하는 새로운 축을 제시해 발견 가치가 높다. 다만 현재 근거는 단일 전임상 모델 중심이라 치료 표준을 바꿀 수준은 아니며, 임상 번역 가능성은 추가 검증이 필요하다.

Hepatocellular carcinoma (HCC), a highly prevalent malignancy, is mostly diagnosed at intermediate and advanced stages. Current monotherapies are limited by poor targeting, severe toxicity, drug resistance, and high metastatic risk, necessitating more effective precision therapeutic strategies. Phot…

In the immunotherapy era, tyrosine kinase inhibitor (TKI) monotherapy is still commonly used for patients with metastatic renal cell carcinoma (RCC) in clinical practice. Prospective evidence on immunotherapy plus tyrosine kinase inhibitor (TKI) after first-line TKI treatment failure is scarce. This…

Extensive studies have implicated glycolytic reprogramming and lactate accumulation in immune evasion. However, clustered regularly interspaced short palindromic repeats (CRISPR)-based in vivo screens systematically interrogating metabolic drivers of immune checkpoint blockade resistance in clear ce…

ccRCC의 면역회피를 젖산 수송체 SLC16A3 중심으로 설명한 점이 핵심이다. 직접적인 환자 치료 변화는 아직 없지만, 대사 표적과 면역치료 저항성 극복 전략을 연결하는 기전적 가치가 크다. 다만 실제 약물화 가능성과 경쟁 구도는 추가 확인이 필요하다.

Relevant pre-clinical models are essential for driving progress in cancer therapy research. Here, we develop a pre-clinical study framework using an injectable orthotopic lung adenocarcinoma (LUAD) model (ORTHO) that replicates key features of human LUAD patients and is dissectible into tumoural and…

Tertiary lymphoid structures (TLS) are organized immune aggregates within the tumor microenvironment that are associated with improved prognosis and immunotherapy response in breast cancer, yet their functional duality and therapeutic potential require further clarification. The present review compr…

Breast cancer is the most prevalent cancer among women globally, and its rising incidence and mortality rates underscore the urgent need for new treatment strategies. Current treatment methods including surgery, radiotherapy, chemotherapy have limited efficacy. In recent years, immunotherapy has att…

L-Arginine (L-Arg) is a key immunometabolite and nitric oxide (˙NO) precursor with therapeutic potential in cancer and immunotherapy. However, its clinical application is hindered by poor bioavailability and uncontrolled dosing. Here, two distinct metal-organic frameworks (MOFs), NH2-MIL-125(T…

Lung squamous cell carcinoma (LUSC) remains a therapeutic challenge with limited biomarkers. The tumor immune microenvironment (TIME) is crucial for progression and immunotherapy response. Because SSX1 and TRIM58 emerged as significant independent prognostic factors, this study investigated their co…

This review provides an introduction to the rapidly expanding field of pharmacogenomics and personalised medicine, with especial relevance and focus for those working in clinical Histocompatibility and Immunogenetics (H&I) laboratories supporting HLA and disease immunogenetic testing and transpl…

Host-microbe interactions critically shape cellular metabolism and immune responses. The bacterial siderophore enterobactin (Ent) is known for pilfering iron from the host, but recent evidence suggests that it may also deliver iron to host mitochondria. Its impact on mitochondrial respiration, howev…